0(0%) Volume: 228,830 1:01AM EST| Market Cap | 97.02 M | P/E(ttm) | |
|---|---|---|---|
| Enterprise Value | 22.53 M | P/B | 1.17 |
CASC has been successfully added into Your Stock Email Alerts list.
You can manage your stock email alerts here.
CASC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
GuruFocus Financial Strength Rank measures how strong a companys financial situation is. It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| vs
industry |
vs
history |
||
|---|---|---|---|
| Cash to Debt | No Debt |
CASC's Cash to Debt is ranked higher than
100% of the 950 Companies in the Global Biotechnology industry. ( Industry Median: 46.43 vs. CASC: No Debt ) Ranked among companies with meaningful Cash to Debt only. |
CASC'
s Cash to Debt Range Over the Past 10 Years
Min: 5.92 Med: 170.56 Max: No Debt Current: No Debt |
| Interest Coverage | No Debt |
CASC's Interest Coverage is ranked higher than
100% of the 467 Companies in the Global Biotechnology industry. ( Industry Median: 10000.00 vs. CASC: No Debt ) Ranked among companies with meaningful Interest Coverage only. |
CASC'
s Interest Coverage Range Over the Past 10 Years
Min: 1060.29 Med: 9999.5 Max: No Debt Current: No Debt |
| F-Score: 2 |
|
| Z-Score: -2.54 |
|
| M-Score: -3.72 |
|
| WACC vs ROIC |
1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank
| vs
industry |
vs
history |
||
|---|---|---|---|
| ROE (%) | -68.80 |
CASC's ROE (%) is ranked lower than
70% of the 864 Companies in the Global Biotechnology industry. ( Industry Median: -33.73 vs. CASC: -68.80 ) Ranked among companies with meaningful ROE (%) only. |
CASC'
s ROE (%) Range Over the Past 10 Years
Min: -163.15 Med: -65.96 Max: 45.34 Current: -68.8 |
| ROA (%) | -58.72 |
CASC's ROA (%) is ranked lower than
72% of the 960 Companies in the Global Biotechnology industry. ( Industry Median: -30.07 vs. CASC: -58.72 ) Ranked among companies with meaningful ROA (%) only. |
CASC'
s ROA (%) Range Over the Past 10 Years
Min: -133.9 Med: -50.43 Max: 24.26 Current: -58.72 |
| ROC (Joel Greenblatt) (%) | -3790.27 |
CASC's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 916 Companies in the Global Biotechnology industry. ( Industry Median: -405.34 vs. CASC: -3790.27 ) Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only. |
CASC'
s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7802.12 Med: -2109.3 Max: 661.83 Current: -3790.27 |
| EBITDA Growth (3Y)(%) | 91.80 |
CASC's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 514 Companies in the Global Biotechnology industry. ( Industry Median: 2.40 vs. CASC: 91.80 ) Ranked among companies with meaningful EBITDA Growth (3Y)(%) only. |
CASC'
s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.2 Med: -8.3 Max: 91.8 Current: 91.8 |
| EPS Growth (3Y)(%) | -13.80 |
CASC's EPS Growth (3Y)(%) is ranked lower than
63% of the 500 Companies in the Global Biotechnology industry. ( Industry Median: -2.80 vs. CASC: -13.80 ) Ranked among companies with meaningful EPS Growth (3Y)(%) only. |
CASC'
s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57 Med: -11.3 Max: 28.8 Current: -13.8 |
| First Eagle Investment 400,000 sh (New) Seth Klarman 25,000,000 sh (New) Paul Tudor Jones 48,760 sh (New) |
| First Eagle Investment 400,000 sh (unchged) Paul Tudor Jones 48,760 sh (unchged) Seth Klarman 25,000,000 sh (unchged) |
(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
Modify your Personalized List of Gurus, or
above to check out all the Gurus, or 
above for the stocks picks of all the institutional investment advisors (>4000) What is Peter Lynch Charts )| Industry: | Biotechnology » Biotechnology NAICS: 325414 SIC: 8731 | |
|---|---|---|
| Compare: | NAS:ARQL, AMEX:PLX, NAS:ATHX, OTCPK:PMCB, NAS:PIRS, NAS:EIGR, AMEX:SYN, NAS:PRQR, NAS:ECYT, NAS:BDSI, OTCPK:CYDY, NAS:GEMP, NAS:GTXI, NAS:CRME, NAS:AXSM, OTCPK:SLNCF, NAS:TTNP, OTCPK:NEWG, NAS:AFMD, NAS:SNSS » details | |
| Traded in other countries: | 3O61.Germany, |
| vs
industry |
vs
history |
||
|---|---|---|---|
| P/B | 1.17 |
CASC's P/B is ranked higher than
88% of the 846 Companies in the Global Biotechnology industry. ( Industry Median: 3.61 vs. CASC: 1.17 ) Ranked among companies with meaningful P/B only. |
CASC'
s P/B Range Over the Past 10 Years
Min: 0.74 Med: 3.92 Max: 23.62 Current: 1.17 |
| Current Ratio | 9.92 |
CASC's Current Ratio is ranked higher than
77% of the 946 Companies in the Global Biotechnology industry. ( Industry Median: 4.18 vs. CASC: 9.92 ) Ranked among companies with meaningful Current Ratio only. |
CASC'
s Current Ratio Range Over the Past 10 Years
Min: 1.67 Med: 11.75 Max: 36.71 Current: 9.92 |
| Quick Ratio | 9.92 |
CASC's Quick Ratio is ranked higher than
77% of the 944 Companies in the Global Biotechnology industry. ( Industry Median: 3.89 vs. CASC: 9.92 ) Ranked among companies with meaningful Quick Ratio only. |
CASC'
s Quick Ratio Range Over the Past 10 Years
Min: 0.95 Med: 11.75 Max: 36.71 Current: 9.92 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Yield on cost (5-Year) | 2.31 |
CASC's Yield on cost (5-Year) is ranked higher than
62% of the 287 Companies in the Global Biotechnology industry. ( Industry Median: 1.75 vs. CASC: 2.31 ) Ranked among companies with meaningful Yield on cost (5-Year) only. |
CASC'
s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.1 Current: 2.31 |
| 3-Year Average Share Buyback Ratio | -18.40 |
CASC's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 547 Companies in the Global Biotechnology industry. ( Industry Median: -10.90 vs. CASC: -18.40 ) Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only. |
CASC'
s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33 Med: -14.2 Max: -0.3 Current: -18.4 |
| vs
industry |
vs
history |
||
|---|---|---|---|
| Price/Net Cash | 1.51 |
CASC's Price/Net Cash is ranked higher than
91% of the 514 Companies in the Global Biotechnology industry. ( Industry Median: 5.88 vs. CASC: 1.51 ) Ranked among companies with meaningful Price/Net Cash only. |
CASC'
s Price/Net Cash Range Over the Past 10 Years
Min: 1.04 Med: 5.16 Max: 39.45 Current: 1.51 |
| Price/Net Current Asset Value | 1.48 |
CASC's Price/Net Current Asset Value is ranked higher than
90% of the 628 Companies in the Global Biotechnology industry. ( Industry Median: 5.64 vs. CASC: 1.48 ) Ranked among companies with meaningful Price/Net Current Asset Value only. |
CASC'
s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.91 Med: 5.14 Max: 36 Current: 1.48 |
| Price/Tangible Book | 1.43 |
CASC's Price/Tangible Book is ranked higher than
87% of the 773 Companies in the Global Biotechnology industry. ( Industry Median: 4.38 vs. CASC: 1.43 ) Ranked among companies with meaningful Price/Tangible Book only. |
CASC'
s Price/Tangible Book Range Over the Past 10 Years
Min: 0.84 Med: 4.6 Max: 72.9 Current: 1.43 |
| Earnings Yield (Greenblatt) (%) | -247.78 |
CASC's Earnings Yield (Greenblatt) (%) is ranked lower than
97% of the 929 Companies in the Global Biotechnology industry. ( Industry Median: -7.90 vs. CASC: -247.78 ) Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only. |
CASC'
s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -305.7 Med: 174.7 Max: 6690.6 Current: -247.78 |
| EPS (TTM) $ | -3.54 |
|---|---|
| Beta | 3.12 |
| Short Percentage of Float | 8.60% |
| 52-Week Range $ | 3.49 - 10.98 |
| Shares Outstanding (Mil) | 22.56 |
| Dec16 | Dec18 | |
|---|---|---|
| Revenue (Mil $) | ||
| EPS ($) | -2.28 | -0.43 |
| EPS w/o NRI ($) | -2.28 | -0.43 |
| EPS Growth Rate (3Y to 5Y Estimate) | N/A | |
| Dividends Per Share ($) | ||
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
My Gurus
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP